HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature.

Abstract
Staphylococci, especially coagulase negative staphylococci (CONS), are responsible for over 75 % of late-onset infections in very low birth weight infants. These infections cause increased length of hospital stay, need for antibiotics, and cost of medical care. Several drug companies have developed and evaluated hyperimmune polyclonal and monoclonal antibodies for the prevention of neonatal staphylococcal infection including 1) Altastaph by North American Biologics Inc., 2) Veronate by Inhibitex Inc., and 3) Pagibaximab by Biosynexus Inc, and Glaxo Smith Kline Inc. We will review the development and status of these potential products. Altastaph is a S. aureus serotype 5 and 8 vaccine induced hyperimmune polyclonal antibody whose development has been placed on hold due to its failure to demonstrate any trend toward efficacy in a recently completed Phase II study. Veronate is a polyclonal antibody obtained by plasmapheresis from donors with high titers of MSCRAMM (microbial surface components recognizing adhesion matrix molecules) activity against CONS whose development has been placed on hold due to its failure to demonstrate effectiveness in a recently completed Phase III study. Pagibaximab is a humanized mouse chimeric monoclonal antibody (previously known as BSYX-A110) directed against lipoteichoic acid (LTA), a major cell wall component of gram-positive bacteria, that has recently completed a Phase II study suggesting efficacy and is being developed further for clinical investigation.
AuthorsL E Weisman
JournalArchives de pediatrie : organe officiel de la Societe francaise de pediatrie (Arch Pediatr) Vol. 14 Suppl 1 Pg. S31-4 (Sep 2007) ISSN: 0929-693X [Print] France
PMID17939955 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulins, Intravenous
  • Veronate
  • altastaph
  • pagibaximab
Topics
  • Adult
  • Age Factors
  • Animals
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Cross Infection (prevention & control)
  • Disease Models, Animal
  • Female
  • Humans
  • Immunoglobulins, Intravenous (administration & dosage, therapeutic use)
  • Infant, Newborn
  • Infant, Premature, Diseases (prevention & control)
  • Infant, Very Low Birth Weight
  • Male
  • Middle Aged
  • Risk Factors
  • Staphylococcal Infections (prevention & control)
  • Staphylococcus aureus
  • Staphylococcus epidermidis
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: